(Reuters) -Anti-wrinkle injection maker Revance Therapeutics has agreed to be bought by privately held Crown Laboratories in a deal valued at $924 million, including debt, seeking scale to compete ...

JOHNSON CITY & NASHVILLE, Tenn., January 21, 2025--(BUSINESS WIRE)--Crown Laboratories, Inc. ("Crown") and Revance Therapeutics, Inc. (NASDAQ: RVNC) ("Revance ...

Crown Laboratories, Inc., a privately held player in the skincare industry, agreed on Monday to acquire Revance Therapeutics, Inc. (NASDAQ:RVNC). Under the terms of the agreement, Crown will commence ...

Revance Therapeutics' share price has been characterised by volatility ever since its IPO - but today shares trade close to an all-time low. The company's focus is on maximising the potential of ...

Revance Therapeutics, Inc. operates in the aesthetics and therapeutics markets, selling Daxxify and RHA Collection of dermal fillers in the U.S. Despite positive guidance for 2024, the Revance stock ...

AbbVie’s Botox is a major blockbuster and king of the anti-wrinkle aesthetics market, but there are new contenders coming for its crown. Revance, which markets its rival anti-wrinkle therapy Daxxify, ...

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that its data will be ...

A pair of phase 3 trials of Revance Therapeutic’s RT002 have hit all their primary and secondary endpoints. The effect of the neuromodulator on wrinkles lasted for six months, suggesting it poses a ...

NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (“Revance”) (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and ...

Shares of Revance Therapeutics surged 18% Thursday after the company announced the Food and Drug Administration had approved Daxxify, a facial injection drug that Revance hopes will challenge Botox’s ...

Increased offer price to $3.65 per share, a $0.55 per share increase Improved offer unanimously approved by Revance Board of Directors Crown to extend tender offer until 11:59 p.m., Eastern Time, on ...